Neurologie up2date, Table of Contents Neurologie up2date 2020; 3(03): 243-256DOI: 10.1055/a-1011-6634 Immunvermittelte und erregerbedingte Erkrankungen des ZNS Neuroborreliose Rick Dersch , Sebastian Rauer Recommend Article Abstract All articles of this category Die Lyme-Borreliose ist die häufigste Zoonose Deutschlands. Bei 3 – 15 % der betroffenen Patienten kommt es zu neurologischen Manifestationen. Im klinischen Alltag bestehen hinsichtlich des Managements der Neuroborreliose oft beträchtliche Unsicherheiten. Der Beitrag fasst den aktuellen Wissensstand zur Klinik, Diagnostik und Therapie der Neuroborreliose zusammen. Full Text References Literatur 1 Halperin JJ. Lyme disease: a multisystem infection that affects the nervous system. Contin Minneap Minn. 2012 18. 1338-1350 Im Internet: (Stand: 25.05.2020) https://www.researchgate.net/publication/233879946_Lyme_Disease_A_Multisystem_Infection_That_Affects_the_Nervous_System/citation/download 2 Huppertz HI, Böhme M, Standaert SM. et al. Incidence of Lyme borreliosis in the Würzburg region of Germany. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 1999; 18: 697-703 3 Dersch R, Rauer S. Neuroborreliose – Diagnostik, Therapie und Verlauf. Nervenarzt 2017; 88: 419-431 4 Fallon BA, Keilp JG, Corbera KM. et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70: 992-1003 5 Robert Koch-Institut – RKI. Meldepflicht für Lyme-Borreliose in Bayern – eine erste Bilanz. Epidemiol Bull. Epidemiologisches Bulletin 8/2015 6 Eliassen KE, Berild D, Reiso H. et al. Incidence and antibiotic treatment of erythema migrans in Norway 2005–2009. Ticks Tick-Borne Dis 2017; 8: 1-8 7 Hofhuis A, Harms M, Bennema S. et al. Physician reported incidence of early and late Lyme borreliosis. Parasit Vectors 2015; 8: 161 8 Wilking H, Fingerle V, Klier C. et al. Antibodies against Borrelia burgdorferi sensu lato among adults, Germany. 2008–2011. Emerg Infect Dis 2015; 21: 107-110 9 Rauer S, Kastenbauer S. Neuroborreliose, S3-Leitlinie. AWMF-Registernummer: 030/071. Im Internet: (Stand: 25.05.2020) https://www.dgn.org/leitlinien/3567-ll-030-071-2018-neuroborreliose 10 Faulde MK, Rutenfranz M, Keth A. et al. Pilot study assessing the effectiveness of factory-treated, long-lasting permethrin-impregnated clothing for the prevention of tick bites during occupational tick exposure in highly infested military training areas, Germany. Parasitol Res 2015; 114: 671-678 11 Pfister HW, Einhäupl KM, Wilske B. et al. Bannwarths syndrome and the enlarged neurological spectrum of arthropod-borne borreliosis. Zentralbl Bakteriol Mikrobiol Hyg Ser Med Microbiol Infect Dis Virol Parasitol 1987; 263: 343-347 12 Reda HM, Harvey HB, Venna N. et al. Case 34–2018: A 58-year-old woman with paresthesia and weakness of the left foot and abdominal wall. N Engl J Med 2018; 379: 1862-1868 13 van Egmond ME, Luijckx G-J, Kramer H. et al. Diaphragmatic weakness caused by neuroborreliosis. Clin Neurol Neurosurg 2011; 113: 153-155 14 Hansen K, Lebech AM. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990 A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain J Neurol 1992; 115: 399-423 15 Kaiser R. Verlauf der akuten und chronischen Neuroborreliose nach Behandlung mit Ceftriaxon. Nervenarzt 2004; 75: 553-557 16 Back T, Grünig S, Winter Y. et al. Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life. J Neurol 2013; 260: 1569-1575 17 Mygland A, Skarpaas T, Ljøstad U. Chronic polyneuropathy and Lyme disease. Eur J Neurol 2006; 13: 1213-1215 18 Fingerle V, Schulte-Spechtel UC, Ruzic-Sabljic E. et al. Epidemiological aspects and molecular characterization of Borrelia burgdorferi sl from southern Germany with special respect to the new species Borrelia spielmanii sp nov. Int J Med Microbiol IJMM 2008; 298: 279-290 19 Fingerle V, Eiffert H, Gessner U. et al. Lyme-Borreliose. 2. Aufl. München: Urban & Fischer in Elsevier; 2017 20 Nadelman RB, Hanincová K, Mukherjee P. et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012; 367: 1883-1890 21 Kaiser R. Variable CSF findings in early and late Lyme neuroborreliosis: a follow-up study in 47 patients. J Neurol 1994; 242: 26-36 22 Djukic M, Schmidt-Samoa C, Lange P. et al. Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol 2012; 259: 630-636 23 Reiber H, Lange P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem 1991; 37: 1153-1160 24 Rupprecht TA, Manz KM, Fingerle V. et al. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis A systematic review and meta-analysis. Clin Microbiol Infect 2018; 24, 12: 1234-1240 25 Rupprecht TA, Lechner C, Tumani H. et al. CXCL13 als Biomarker der akuten Neuroborreliose. Überprüfung des prädiktiven Wertes in der klinischen Routine. Nervenarzt 2014; 85: 459-464 26 van Burgel ND, Bakels F, Kroes ACM. et al. Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid. J Clin Microbiol 2011; 49: 2027-2030 27 Hofmann H, Fingerle V, Hunfeld K-P. et al. Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society. Ger Med Sci 2017; 15: Doc14 28 Raffetin A, Saunier A, Bouiller K. et al. Unconventional diagnostic tests for Lyme borreliosis: a systematic review. Clin Microbiol Infect 2020; 26: 51-59 29 Oksi J, Nikoskelainen J, Hiekkanen H. et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis 2007; 26: 571-581 30 Solheim AM, Ljøstad U, Mygland Å. Six versus two weeks treatment with doxycycline in Lyme neuroborreliosis: the protocol of a multicentre, non-inferiority, double-blinded and randomised controlled trial. BMJ Open 2019; 9: e027083 31 Dersch R, Sarnes AA, Maul M. et al. Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol 2015; 262: 2572-2577 32 Kortela E, Kanerva M, Puustinen J. et al. Oral doxycycline compared to intravenous ceftriaxone in the treatment of Lyme neuroborreliosis: a multicentre, equivalence, randomized, open-label trial. Clin Infect Dis 2020; Mar 5;ciaa217 33 Jowett N, Gaudin RA, Banks CA. et al. Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope 2017; 127: 1451-1458 34 Dersch R, Hottenrott T, Schmidt S. et al. Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review. BMC Neurol 2016; 16: 189 35 Dersch R, Freitag MH, Schmidt S. et al. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review. Eur J Neurol 2015; 22: 1249-1259 36 Kalish RA, Kaplan RF, Taylor E. et al. Evaluation of study patients with Lyme disease, 10–20-year follow-up. J Infect Dis 2001; 183: 453-460 37 Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther 2014; 12: 1103-1135 38 Rebman AW, Aucott JN. Post-treatment Lyme Disease as a Model for Persistent Symptoms in Lyme Disease. Front Med 2020; 7: 57 39 Lantos PM, Auwaerter PG, Wormser GP. A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease. Clin Infect Dis Off Publ Infect Dis Soc Am 2014; 58: 663-671 40 Klempner MS, Hu LT, Evans J. et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92 41 Krupp LB, Hyman LG, Grimson R. et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60: 1923-1930 42 Sjöwall J, Ledel A, Ernerudh J. et al. Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study. BMC Infect Dis 2012; 12: 186 43 Berende A, ter Hofstede HJM, Vos FJ. et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. N Engl J Med 2016; 374: 1209-1220 44 Berende A, Ter Hofstede HJM, Vos FJ. et al. Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis. Neurology 2019; 92: e1447-e1455
